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The NR4A1–NR4A3 (Nur77, Nurr1, and Nor-1) subfamily of nuclear receptors is a
group of immediate early genes induced by a pleiotropy of stimuli including peptide
hormones, growth factors, cytokines, inflammatory, and physiological stimuli, and
cellular stress. NR4A receptors function as potent sensors of changes in the cellular
microenvironment to control physiological and pathological processes through genomic
and non-genomic actions. NR4A receptors control metabolism and cardiovascular and
neurological functions andmediate immune cell homeostasis in inflammation and cancer.
This receptor subfamily is increasingly recognized as an important molecular connection
between chronic inflammation, altered immune cell responses, and cancer development.
In this review, we examine how transcriptome analysis identified NR4A1/NR4A2
receptors as transcriptional regulators in mesenchymal stromal cell (MSC) migration,
cell cycle progression, and cytokine production to control local immune responses. In
chronic inflammatory conditions, such as rheumatoid arthritis, NR4A receptors have
been shown to modify the activity of MSC and fibroblast-like stromal cells to regulate
synovial tissue hyperplasia, pathological angiogenesis, and cartilage turnover in vivo.
Additionally, as NR4A1 has been observed as a major transcriptional regulator in
tumor–stromal communication controlling tumorigenesis, we discuss how advances
in the pharmacological control of these receptors lead to important new mechanistic
insights into understanding the role of the tumor microenvironment in health and disease.
Keywords: NR4A nuclear receptors, inflammatory homeostasis, fibroblast-like and mesenchymal stromal cells,
angiogenesis, cancer immunity and tumorigenesis, NR4A control of tumor-stromal communication
NR4A SUBFAMILY OF NUCLEAR RECEPTORS
The NR4A1–NR4A3 (Nur77/NGFI-β/TR3, Nurr1/TINUR/NOT, and Nor-1/MINOR/CHN)
subfamily of nuclear receptors is a group of immediate early genes induced by a
pleiotropy of stimuli including peptide hormones, growth factors, cytokines, inflammatory
and physiological stimuli, and cellular stress. NR4A receptors function as potent
sensors of changes in the cellular microenvironment to control physiological and
pathological processes through genomic and non-genomic actions. NR4A receptors
control metabolism, vascular homeostasis, and cardiovascular and neurological functions
and mediate immune cell homeostasis in inflammation and cancer. The majority
of NR4A activity is due to direct activation or repression of transcriptional target
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expression. A growing body of information demonstrates
direct non-genomic roles of NR4As through posttranslational
modifications and interactions with binding partners (recently
reviewed by Herring et al., 2019). NR4A receptors bind directly
as monomers or homodimers to promoter regions of target
genes that contain the NBRE response element (AAAGGTCA).
Furthermore, NR4A receptors can dimerize with retinoid X
receptor (RXR) nuclear receptors and bind to a DR5 (direct
repeat with 5-bp length spacer) motif, providing a mechanism
for NR4A receptors to regulate distinct target genes in vivo.
Similar to NR4A receptors, RXR is also a member of the nuclear
receptor subfamily controlling pathways associated with cell
development, differentiation, metabolism, and cell death (Evans
and Mangelsdorf, 2014).
Expression levels, subcellular localization, and the cellular
context/environment can influence NR4A tissue-specific
functional roles as observed in several cancers and diseases
characterized by chronic inflammation (Zhao and Bruemmer,
2010; Mohan et al., 2012; Murphy and Crean, 2015). The
cross talk of the NR4A1–NR4A3 subfamily members with
various oncogene and tumor suppressor pathways is well-
established (Safe et al., 2014; Beard et al., 2015; Wan et al., 2020).
Extensive numbers of studies indicate that NR4A genes can act
paradoxically either as oncogenes or as tumor suppressors. For
example, they serve as oncogenes in lung cancer, melanoma,
and colorectal cancer (CRC) but display tumor suppressor
roles in acute myeloid leukemia (AML), breast cancer, and
metastatic ovarian cancer. The NR4A1–NR4A3 cross talk with
pro-tumorigenic or tumor-suppressive signaling pathways
underwrites a dichotomous and context-dependent role(s) for
members of this receptor subfamily (reviewed by Beard et al.,
2015, and Wan et al., 2020).
Disordered stromal cell function, including altered signaling
and secretion of paracrine factors, has been linked to disease
progression of cancer and inflammatory disorders (Spaeth
et al., 2008; Nissen et al., 2019). The molecular cross talk
between cancer cells and their surrounding stroma and tumor
microenvironment (TME) has a crucial role in the regulation
of tumorigenesis and disease advancement. Evidence on the
association between NR4A1–NR4A3 functional activities, their
influence on the tumor–stromal cell environment, and the impact
on disease pathogenesis is emerging. Innovative studies are
providing compelling support that NR4A orphan receptors,
by changing the local cellular microenvironment, can mediate
inflammatory responses, promote angiogenesis, control cellular
metabolism and survival, and alter cancer cell immunity to
influence the course and outcome of disease. The purpose of
this review is to discuss how recent advances in NR4A nuclear
receptor biology are leading to important new mechanistic
insights into understanding their role in stromal cells and the
TME in health and disease.
TME AND TUMOR STROMA
The TME is composed of non-malignant host cellular and non-
cellular components, including cells of the immune system, blood
cells, endothelial cells, fat cells, and the stroma. The tumor
stroma is an essential component of the TME and is composed
of cellular and non-cellular connective tissues that support
functional tissues, including fibroblasts, mesenchymal stromal
cells (MSCs), osteoblasts, chondrocytes, and the extracellular
matrix (ECM). While specialized cells of the TME, such as
endothelial cells, pericytes, adipocytes, and immune cells, can be
included as constituents of the stromal compartment, these cells
are more accurately defined as non-stromal cells within the TME
(Valkenburg et al., 2018).
It is well-established that the TME plays a pivotal role in tumor
progression, and together with cells of the stroma, this milieu
plays a major role in maladapting and promoting tumor survival
and progression. As outlined, the TME consists of a complex
system of heterogeneous cancer cells alongside local host cells
and non-stromal components of the TME including adipocytes,
pericytes, and immune cells, which also contribute to the tumor–
stromal communication (de Groot et al., 2017). Within this
environment are fluxes in multiple signaling molecules such as
cytokines and adenosine, alterations in metabolic states, regions
of hypoxia, acidosis, fibrosis, structural/architectural breakdown
from factors such as matrix metalloproteinases (MMPs), and
enhanced angiogenesis concurrent with inadequate perfusion,
leading to poor nutrient supply (Liotta and Kohn, 2001; De
Palma et al., 2017; Binnewies et al., 2018; Chandler et al., 2019).
This complex environment is not only a consequence of cancer
progression but also a pivotal factor in aiding its progression
(Liotta and Kohn, 2001; Binnewies et al., 2018).
The tumor stroma, like its normal counterpart, is essential
for tissue structure and remodeling. It is a vital component of
the TME involved in tumorigenesis, cancer progression, and
metastasis (Valkenburg et al., 2018). In addition to the main
components of the stroma, including MSCs, osteoblasts, and
the ECM, the tumor stroma also has a high abundance of
cancer-associated fibroblasts (CAFs). While stromal cells display
antitumor activities in normal conditions, in the background
of such altered and harsh environments, stromal cells respond
and undergo phenotypic changes and in turn play a pivotal
role in influencing tumor progression (de Groot et al., 2017).
One of the most notable maladaptive responses is the activation
of the hypoxia inducible factor-1α (HIF-1α)-dependent gene
transcription in hypoxic tumors, leading to metabolic changes
and increased oxygen supply, which aid tumor survival and
progression, leading to worse outcomes for patients (Semenza,
2010). Predictably, several of these tumor-associated alterations,
or factors which promote or maintain the complexity of these
transformed systems, are targets for cancer therapy design, for
example, targeting tumor angiogenesis, reprogramming cellular
metabolism, and adjusting inflammatory responses leading to
altered immune cell populations, with the goal of correcting
the environment, which aids in the survival of cells that
promote tumorigenesis (Semenza, 2010; Naing et al., 2018; Wang
et al., 2018). As we outline herein, leading reports elucidating
the novel regulatory role of the NR4A1–NR4A3 receptors
implicate these receptors as important mediators controlling
these crucial cellular processes leading to changes in the TME and
cancer progression.
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(I) NR4A1–NR4A3 RECEPTORS, THE
LOCAL INFLAMMATORY RESPONSE, AND
TUMOR STROMAL CELLS
Tumor–stromal communication plays an important role in not
only cancer initiation but also the proliferation and metastasis
of these cells into distant organs, potentially causing cancer
recurrence. Inflammatory cytokines and growth factors released
by MSC, CAFs, and tumor-associated macrophages (TAMs)
initiate a signaling cascade and create a microenvironment
conducive to tumorigenesis (Guo and Deng, 2018; Leuning
et al., 2018). In 2014, Zhou and colleagues revealed a distinct
mechanism by which the microenvironment stimulates breast
cancer cell invasion and metastasis. With a genome-wide cDNA
screen, it was identified that inflammation-induced NR4A1
(NR4A2 and NR4A3 also respond) is a critical factor for
the activation of TGF-β/SMAD-mediated breast cancer cell
migration, invasion, and metastasis in vitro and in vivo. Loss
of NR4A1 inhibits TGF-β-induced epithelial-to-mesenchymal
transition (EMT), revealing a novel mechanism by which the
microenvironment stimulates breast cancer cell invasion and
metastasis (Zhou et al., 2014).
Furthermore, a recent study proposes a far-reaching model
(using serial single-cell RNA sequencing) of paracrine signaling
mediated by the activity of cyclooxygenase (COX-2) enzyme
activity and production of the proinflammatory mediator,
prostaglandin E2 (PGE2), by prolactin receptor (PLR+)-
expressing tumor cells (Zheng et al., 2019). In this in vivo
model of tumorigenesis, stromal cell expression and activity
of all three NR4A receptors are activated by the enhanced
secretion of PGE2 by neighboring tumor cells. NR4A receptors
rapidly heterodimerize with the RXR, and a stromal cell
NR4A–RXR complex induces the transcription, production,
and secretion of the peptide hormone prolactin. The secreted
hormone feeds back to neighboring tumor cells, increasing
their proliferation, leading to tumorigenesis. Importantly, it was
found that induction of stromal NR4A expression by PGE2
selectively stimulates expression of NR4A receptors but not
the RXR family (Zheng et al., 2019). COX-2, prolactin, and
prolactin receptor show consistent differential expression in
tumor and stromal compartments across several human cancers.
The observed cellular paracrine cross talk may be important
factors in the efficacy of the anti-inflammatory COX-2 inhibitors
in cancer suppression.
The COX-2/PGE2/NR4A signaling findings complement
previous studies where NR4A has been shown to be a regulator
of stromal and immune cell functions (Murphy and Crean,
2015) and linked to the expression of prolactin expression in
inflammatory joint disease (McCoy et al., 2015). Further, in
rheumatoid arthritis (RA), psoriasis, and colon cancer, the NR4A
subfamily has previously been singled out as a downstream
effector of prostaglandin (PGE) signaling. PGE2 potently induces
NR4A2 expression levels via a cAMP/PKA-dependent pathway
(Holla et al., 2011; McMorrow and Murphy, 2011). Studies
by Holla et al. (2011) suggest that the molecular cross talk
between PGE2 and NR4A2 is central to controlling CRC survival
mediated through the regulation of apoptosis by blocking
cleavage of caspase-3, with NR4A2 playing a central role as
a point of transcriptional integration coupling eicosanoid and
metabolic pathways.
Chronic inflammation can generate an immunosuppressive
microenvironment that allows advantages for cancer formation
and progression. MSCs, and their secreted paracrine factors,
can modulate inflammatory and immune responses (Fontaine
et al., 2016). The immunosuppressive environment has been
shown to be PGE2 regulated in several cancers (Wang and
Dubois, 2018). Recent investigations into the adaptation of
the leukemic mesenchymal microenvironment reveal a novel
COX-2/PGE2-NR4A/WNT signaling axis, correlating chronic
inflammation with changes in cellular metabolism, leading
to reduced immune surveillance (Wu et al., 2018). Reduced
secretion of prostaglandins by the mesenchymal inhibition of
COX-2 led to decreased expression of NR4A receptors and
regulatory T-cell (Treg) genes, FOXP3 and CTLA4, in the
MSC-cocultured CD34+ cells. The significance of these findings
highlights that upregulated NR4A-WNT/β-catenin signaling
functions to attenuate antileukemic immunity by upregulating
Tregs and blocking the production of leukemia-reactive CD8+
cytotoxic T lymphocytes.
Tregs, which prevent overt immune responses and
autoimmunity, have been shown to accumulate aberrantly
in some types of TMEs to suppress antitumor immunity
and to sustain the establishment of an immunosuppressive
environment. Impeding Treg-mediated immune tolerance
is central when considering cancer immunotherapy. Mice
lacking NR4A1 and NR4A2 genes, specifically in Treg cells,
show resistance to tumor growth in transplantation models
without exhibiting any serious systemic autoimmunity (Hibino
et al., 2018). Treatment with a chemotherapeutic agent,
camptothecin, together with a COX-2 inhibitor was found to
inhibit induction and transcriptional activity of NR4A factors,
and they synergistically display antitumor effects in vivo (Hibino
et al., 2018). Thus, genetic inactivation or pharmacologic
inhibition of NR4A receptors can unleash effector activities of
CD8+ cytotoxic T cells and stimulate potent antitumor immune
responses within the TME. Chen et al. (2019) further ascertained
that an NFAT–NR4A axis controls the expression of several
inhibitory receptors and that treatment of tumor-bearing mice
with CAR-T cells, lacking all three NR4A receptors, results in
tumor regression and prolonged survival. Collectively, these
studies indicate translational and therapeutic implications
in the development of effective TME anticancer therapies by
modulating NR4A receptor function in tumor-infiltrating T cells.
It is thought that MSCs exhibit a gain of function which
allows them to preferentially migrate toward tumor sites as
they would to a wound (Spaeth et al., 2008). The molecular
mechanisms behind this movement are still not fully elucidated
but are becoming more recognized as important, owing to the
fact that MSCs within the TME are often linked with poorer
prognosis, augmenting angiogenesis, tumor formation, and
metastasis (Karnoub et al., 2007). In breast cancer, for example,
many studies have used the MDA-MB-231 cell line to examine
the plausible chemotactic factors responsible for this movement
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(Dwyer et al., 2007; Lin et al., 2008). This MDA-MB-231 cell
line models the most invasive and migratory triple-negative
(TN) form of breast cancer (Lanning et al., 2017). Signaling
molecules including SDF-1α, TGF-β, IL-6, PDGF, MCP-1, and
cyclophilin B were identified as trophic factors associated with
MSC recruitment, but it is proposed that they are not working
alone and that additional signaling pathways, transcriptional
mechanisms, and regulatory elements need to be ascertained
to fully understand the complexity of the molecular processes
involved. The NR4A family is associated with the migration of
MSCs and their movement into tumor sites. In a study examining
the difference in gene profiles between migratory and non-
migratory MSCs, it materialized that, of the 12 genes which
displayed differential expression, both NR4A1 and NR4A2 genes
showed the highest expression change in the migratory variety in
response to SDF-1α and PDGF, signifying a potential regulatory
role for these transcription regulatory factors (Maijenburg
et al., 2012). Enhanced NR4A1 and NR4A2 expression levels in
MSCs lead to increased cytokine and growth factor production,
suggesting that these receptors regulate migratory MSCs with the
capacity to specifically modulate the local immune response.
(II) NR4A196NR4A3 RECEPTORS, THE
TME, AND STROMAL CELL HYPERPLASIA
One of the first indicators that normal cells may be switching to a
cancerous phenotype is the initiation of hyperplasia and changes
in metabolic activity, where the tissue of an organ is enlarged due
to an abnormal increase in cell reproduction and proliferation
(Dupont et al., 1993). Recent studies discerning the associations
with stromal and non-stromal cells of the TME and NR4A1–
NR4A3-dependent changes on cell density, metabolic activity,
cell hyperplasia, survival, and invasion are described herein.
In breast cancer, the density of the breast tissue, “how many”
stromal cells it has, has often been associated with increased
cancer risk and poorer prognosis. A functional role for NR4A2
has been suggested by a study examining the mechanisms behind
obesity-associated breast cancer risk (Ghosh et al., 2010). In
human adipose stromal cells (ASCs), NR4A2 is established
to be a key regulator of aromatase gene transcription. The
function of aromatase is the enzymatic conversion of androgen
to estrogen, which catalyzes the final and rate-limiting step in
estrogen biosynthesis. This increase in aromatase activity and
subsequently estrogen levels in adipose tissue is proposed to
be one of the main causal factors in the substantial increased
likelihood that women classified as obese will develop breast
cancer (Bulun et al., 2005). Ghosh et al. hypothesized that with
increased breast cell density, there is a concomitant decrease in
the tumor-suppressive function of BRCA1 and NR4A receptors.
When NR4A2 expression and activity are depleted in isolated
human ASCs, there is a substantial increase in aromatase gene
expression and, therefore, estrogen biosynthesis, increasing the
likelihood of breast cancer occurrence (Ghosh et al., 2010).
As a major component in the breast cancer
microenvironment, ASCs are capable of secreting large
quantities of metabolic substrates, such as fatty acids, to establish
a metabolic TME. NR4A1 has been identified as a regulator for
fatty acid uptake in breast cancer, leading to restrained fatty
acid metabolism and inhibiting breast cancer progression both
in vitro and in vivo. This study reveals that NR4A1 binds and
recruits a corepressor molecule to the promoter regions of CD36
(also known as FA translocase) and fatty acid-binding protein 4
(FABP4), leading to transcriptional suppression, which hampers
fatty acid uptake, leading to the inhibition of cell proliferation
and impeding tumor cell growth in vivo (Yang et al., 2020). In
contrast, in a study of melanoma, NR4A1 contributes to the
metabolic adaptation of melanoma cells by regulating fatty acid
uptake and oxidation (Li et al., 2018). The NR4A1-dependent
metabolic adaptation protects melanoma cells undergoing loss
of attachment (LOA) to the ECM and supports the survival
of circulating tumor cells in the circulation. As highlighted,
eicosanoid signaling and fatty acid metabolism through PGE2-
mediated upregulation of NR4A2 receptors in colon cancer cells
have been established (Holla et al., 2011). The studies propose
that COX-2-derived PGE2 potentially regulates an adaptive
shift in metabolism and NR4A2 activity central to this process.
NR4A2 transcriptional activity increases fatty acid oxidation
by inducing the expression and activity of several enzymes
central to the fatty acid metabolic pathway. Collectively, these
studies indicate that alteration of NR4A activity may fine-tune
an adaptive shift to energy utilization via fatty acid oxidation, a
metabolic adjustment that is observed in several types of cancer.
The role of NR4A1 in the TME has been further recognized
with in vivo studies of tumor metastatic spreading models in
wild-type (NR4A1+/+) mice and NR4A1−/− mice (Hanna et al.,
2015; Li et al., 2017). Expression of host NR4A1 was identified
as a critical factor in antitumor metastasis because, in the
absence of NR4A1, metastatic spreading was greatly accelerated
(Li et al., 2017). Furthermore, this study reveals two potential
key mechanisms by which the absence of NR4A1 expression
facilitates cancer cell invasion and metastasis. Lack of NR4A1
in TME macrophages promotes inflammatory cytokine TNF-
α production, which stimulates cancer cells to undergo EMT
and promotes invasive properties. In addition, lack of NR4A1
results in reduced levels of colony-stimulating factor-1 receptor
(CSF-1R) expression, which decreases the migratory capacity
of inflammatory cells and subsequently hinders cell chemotaxis
and tumor infiltration. These results unveil a novel function
of NR4A1 in regulating tumor invasion and metastasis, which
is consistent with a previous study reporting that NR4A1-
deficient mice specifically lack “patrolling monocytes,” resulting
in increased cancer lung metastasis in vivo (Hanna et al., 2015).
NR4A1 protein expression is also decreased in the mouse
basal-like mammary tumors during the tumor progression
process and in a large proportion of human TN breast cancer
(TNBC) tumors. The low expression of NR4A1 protein in human
TNBC samples is associated with advanced tumor stage, lymph
node metastasis, and disease recurrence. Expression of NR4A1 in
TNBCMDA-MB-231 cells significantly inhibits the proliferation,
viability, migration, and invasion of these cells in culture and
in vivo and the growth and metastasis of these cell-derived
tumors in mice (Wu et al., 2017). These results demonstrate
that NR4A1 functions to inhibit the initiation and growth of
the MDA-MB-231 cell-derived tumors in mice by reducing their
proliferation rate.
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Constitutivemigration and TGFβ-inducedmigration of breast
cancer cells are reliant on nuclear and extranuclear expression of
NR4A1, respectively, and it has been shown that selective NR4A1
antagonists inhibit both pathways by decreasing the NR4A1-
dependent expression of β1-integrin, inhibit TGFβ-induced
nuclear export of NR4A1, and induced EMT (Hedrick et al.,
2016). It has been recognized in CRC tissues that aberrant NR4A1
expression in cancer tissues and cells of the TME acts to promote
cell growth and survival by serving as an important mediator
of the WNT/β-catenin and AP-1 signaling pathways (Wu et al.,
2011). Moreover, the receptor can promote metastasis and
invasion through controlling the MMP9/E-cadherin axis (Wang
et al., 2014) and β1-integrin (Hedrick et al., 2017) and forming
a feedforward loop with β-catenin under hypoxic conditions (To
et al., 2014). These studies propose a novel molecular basis for
understanding the biological properties of tumorigenesis and
reveal that selective targeting of NR4A1 functional activity may
represent a mechanism for altering cancer metastasis in vivo.
(III) NR4A EXPRESSION AND ACTIVITY IN
TUMOR ANGIOGENESIS
Angiogenesis is one of the key factors associated with cancer
progression, with studies finding that the balancing levels of
pro- and anti-angiogenic factors, including vascular endothelial
growth factor (VEGF) levels, in tissue reflect the aggressiveness
with which tumor cells spread. Additional cellular players
involved in angiogenesis include CAFs (Kalluri, 2016; Santi
et al., 2018). VEGF has been found to potently activate the
expression and functional activity of all three NR4A members,
and in NR4A1−/− knockout mice, tumor growth, angiogenesis,
and microvessel permeability are almost completely inhibited,
further purporting a critical mode for these orphan receptors in
tumorigenesis (Zeng et al., 2006). Recent studies strengthen this
significant body of work, further demonstrating that NR4A1 is
essential for VEGF-A-induced pathological angiogenesis, tumor
growth, and metastasis in vivo (Ye et al., 2019; Chen et al., 2020).
Extending previous findings that tumor growth was inhibited in
NR4A1 knockout mouse models, metastasis of colorectal tumor
was completely inhibited in NR4A−/− mice. Tumor masses
were increased by ∼70% and decreased by ∼40% in transgenic
EC-NR4A1-S mice and EC-NR4A1-DN mice, in which the
full length and a dominant negative mutant of NR4A1 were
induced and specifically expressed in the mouse endothelium.
In human disease, NR4A1 is highly expressed in the vasculature
and tumor cells of human melanoma and CRC tissues, but
not in normal tissues. Furthermore, tumor angiogenesis and
modulation of genes associated with angiogenesis were critically
reduced in tumor tissues treated with NR4A1 shRNAs and
selective minigenes (Ye et al., 2019; Chen et al., 2020). Silencing
endothelial NR4A1 inhibits the proliferation and migration of
tumor cells, indicating that the NR4A1 receptor functions as a
regulator of tumor growth and metastasis in vivo. Together, these
studies demonstrate that NR4A1 is a prospective therapeutic
target with translational potential for several human cancers by
targeting the vasculature within the TME.
(IV AND V) CAFS, INTRA-TUMORAL
FIBROSIS, AND NR4A RECEPTORS
CAFs are the dominant cell type within the stroma of tumors.
They orchestrate paracrine pro-tumorigenic signaling with
adjacent tumor cells, thus exacerbating the hallmarks of cancer
and accelerating tumor malignancy. In breast cancer, up to
80% of the normal fibroblasts in breast tissue acquire the CAF
phenotype during cancer progression (Kalluri, 2016; Santi et al.,
2018). Molecular insights into the transcriptional programs
that enable the oncogenic function of CAFs are emerging
(Chan et al., 2018). The complete human NR profile in CAFs
from clinical cutaneous squamous cell carcinoma (SCC) biopsies
has recently been accomplished (Chan et al., 2018). Interestingly,
both NR4A2 and NR4A3 are significantly upregulated in
microdissected CAFs (n = 10). A highly similar NR4A2/NR4A3
profile was observed between the microdissected CAFs and
explanted CAFs, indicating that the NR profile of SCC CAFs
is retained during in vitro culture. Pharmacological targeting
of specific driver NRs in CAFs diminished SCC invasiveness,
proliferation, drug resistance, energy metabolism, and oxidative
stress status.
Tumors have often been described as “wounds that do not
heal,” and as such, it is not unforeseen that fibrosis not only is a
major consequence of progressing tumors but also plays a causal
role in their progression (Chandler et al., 2019; Chen and Song,
2019). It is CAFs within the stroma that are themain protagonists
of such fibrosis in cancers, while other cells, such as immune cells,
may also contribute in secreting fibrotic activators (Yamauchi
et al., 2018). To date, the specific cell origin of these CAFs
remains unknown, with the likelihood that they are derived from
diverse cell types within the stroma (Cirri and Chiarugi, 2011;
Kalluri, 2016). Interestingly, several factors involved in fibrosis
are similarly implicated in multiple stages of cancer progression.
Numerous ECM proteins, including fibronectin, are secreted
by CAFs and have been shown to enhance tumor aggression,
invasion, and metastasis. TGFβ, a major pro-fibrotic factor, has
been shown to drive the differentiation of fibroblasts to CAFs,
which aid in tumor aggression and invasiveness (Kalluri, 2016).
Additionally, TGFβ receptor activation is responsible for the
secretion of multiple MMPs within tumors, which play pivotal
roles in tissue breakdown enhancing the metastatic capabilities
(Hawinkels et al., 2014). Of note, activation of NR4A1 in breast
cancer enhances TGFβ3 signaling, potentiating its oncogenic
activities, by inducing SMAD7 degradation. Moreover, NR4A1
was shown to enhance TGFβ-induced EMT, a process later
shown to be dependent on NR4A1 nuclear export. These studies
confirm a pivotal role for NR4A1 in mediating TGFβ/p38-
dependent induction of β-catenin in TNBC migration and
invasion (Hedrick et al., 2016, 2017; Hedrick and Safe, 2017).
In a separate analysis, inflammatory cytokines, IL-1β, and
TNF-α potently induce NR4A2 expression, which, in the
presence of TGFβ, potentiates SMAD activation of fibrosis
and cancer development (Zhou et al., 2014; Palumbo-Zerr
et al., 2015). These responses are significantly amplified when
NR4A is overexpressed, leading to TGFβ/SMAD-induced
EMT and invasion by interacting with and promoting
Frontiers in Cell and Developmental Biology | www.frontiersin.org 5 February 2021 | Volume 9 | Article 589770
Crean and Murphy NR4A Control of Tumor-Stromal Communication
AXIN2-RNF12/ARKADIA-induced SMAD7 degradation to
enhance the expression of activated TGFβ type I receptor
(TβRI). These observations suggest that both NR4A1 and
NR4A2 are important mediators in responding to inflammatory
stimuli by activating TGFβ signaling and underline the need
for further identification of NR4A1–NR4A3-specific functions
in controlling intra-tumoral fibrotic pathways and the impact
on EMT.
The functional activity of NR4A3 in breast and lung cancer
progression has been examined, and a notable association
between this NR4A family member and the tumor suppressor
p53 was determined (Fedorova et al., 2019). NR4A3 gene
expression is a direct transcriptional target of p53, suggesting
that the NR4A3 functional activity and tumor suppressor role
in cancer progression is activated by p53. As part of this study,
patient survival analysis, using a publicly available clinical data
repository, was conducted, establishing that high levels of NR4A3
expression positively correlate with increased survival rates for
patients with breast and lung cancers. Thus, these studies reveal
thatNR4A3 is a novel transcriptional target of p53, which triggers
apoptosis and has a tumor-suppressive role in breast and lung
cancers (Fedorova et al., 2019). Whether NR4A3 is a bona fide
tumor suppressor needs further elucidation. However, several
lines of evidence support this notion. In NR4A1/NR4A3 double-
knockout mice, it was reported that loss of these two genes can
result in the development of AML, due to uncontrolled expansion
of myeloid progenitor cells (Boudreaux et al., 2012, 2019).
(VI) NR4A1-NR4A3 RECEPTORS IN
RHEUMATIC DISEASES
NR4A1–NR4A3 expression is elevated in synovial tissue
MSC and fibroblast-like stromal cells (FLSs), macrophage,
endothelium, cartilage, and PGE2-stimulated chondrocytes from
patients with RA, psoriatic arthritis, or osteoarthritis, making
NR4A receptors attractive targets in rheumatic and skin
diseases (McMorrow and Murphy, 2011; Marzaioli et al.,
2012; Shi et al., 2017; Xiong et al., 2020). Stromal cell
hyperplasia and development of a “tumor-like pannus” are
characteristics of chronic inflammatory diseases including RA
and psoriatic arthritis (Bottini and Firestein, 2013). Expression of
NR4A1/NR4A2 subfamily members are significantly upregulated
in the pannus tissue and are mediators of cytokine, growth factor,
and prostanoid (PGE2) action contributing to the hyperplastic
and invasive phenotype of FLSs that leads to the modulation of
MMP production and cartilage homeostasis (Mix et al., 2012).
POTENTIAL FOR TARGETING NR4A
RECEPTORS
NR4A receptors’ expression and function in stromal cells and
their influence on non-stromal cells of the TME are emerging as
a promising area for the promotion of novel therapeutic targets
in the treatment and prevention of human cancer progression.
Developments on mechanisms of NR4A silencing and/or
strategies for their activation are leading to new therapeutic
interventions (Lee et al., 2014; Safe et al., 2014; Boudreaux et al.,
2019). Over the last decade, multiple agents have been identified
to modulate NR4A1–NR4A3 expression and functional activity
in vitro and in vivo (Safe et al., 2014, 2016). While previously
it was understood that NR4A receptors were not “druggable”
targets given their bulky and inhospitable ligand binding domain
(de Vera et al., 2019), endogenous mediators, including fatty
acids, have been shown to act as potent modulators (de Vera
et al., 2016, 2019). These modulating agents, both agonists and
antagonists, have been examined extensively, with their binding
capabilities and exact mechanisms of action being rationalized
systematically (Safe et al., 2014, 2016; Munoz-Tello et al.,
2020). More recently, Conneely et al. have made important
therapeutic innovations in AML with the identification of several
drugs that modulate NR4A1/NR4A3 expression and function
(Boudreaux et al., 2019). Both NR4A1 and NR4A3 are silenced in
AML and display tumor-suppressing qualities suppressing MYC
activity. NR4A1/NR4A3 silencing in AML is mediated through
the blockade of transcription elongation, while treatment with
dihydroergotamine (DHE) rescued NR4A silencing and allowed
their tumor-suppressing ability to reactivate with concomitant
slowing of AML progression in vivo (Boudreaux et al., 2019).
Thus, recent findings (summarized in Figure 1) support the
targeting of NR4A receptors as potential specific therapeutic
targets in enhancing the efficacy of cancer treatments and
include (i) pursuing NR4A receptors (downstream of COX-
2/PGE2 activity) as key regulators of prolactin production and
signaling by stromal cells to reduce cancer cell proliferation and
tumorigenesis; (ii) modulating NR4A2 transcriptional activity
as a regulator of fatty acid utilization in CRC and aromatase
transcription and production of estrogen in TNBC; (iii)
controlling NR4A1–NR4A3 as regulators of angiogenesis, with
the functional activity of NR4A1 in mediating VEGF-A-induced
pathological/tumor angiogenesis facilitating cell proliferation
and cancer cell migration; (iv) CAF activity, migration of MSCs
and immune cells into tumor sites, and their role as mediators of
EMT and cell metastasis; and (v) further analyzing the molecular
interactions of this subfamily with the ECM, TGFβ/SMAD
signaling, and control by altered p53 activity, which could also
prove extremely beneficial to elucidating the NR4A1–NR4A3-
dependent molecular mechanism(s) controlling cell survival,
hyperplasia, and death and altering immune tolerance against
cancer. Modulation of NR4A1–NR4A3 receptors as therapeutic
targets in cancer biology reveals a novel category of mechanism-
based therapies, and future efforts, due to their dichotomous
responses, should involvemeticulous evaluation of the cancer cell
type targeted andmoreover the method(s) of drug delivery, given
the tissue- and cell-specific functional roles that NR4A receptors
display in controlling cancer biology.
SUMMARY
While it is well-established that the initiation and development
of cancer is a disease brought about by mutations in the
cancer cells themselves, there is no doubt that the TME
and stromal microenvironment are critically important for
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FIGURE 1 | Distinct cell-specific functions controlled by NR4A1–NR4A3 nuclear receptors in the TME–stromal microenvironment. (i) Stromal fibroblasts: NR4A
receptor dimerization with RXR receptors (downstream of pro-inflammatory COX-2/PGE2 activity) functions as potent regulators of prolactin production/signaling by
stromal cells. (ii) Adipocytes: NR4A activity promotes an adaptive shift to energy utilization via fatty acid oxidation with NR4A2 regulating aromatase transcription and
production of estrogen in TNBC. (iii) Endothelium and CAFs: NR4A receptors regulate VEGF-A-induced pathological/tumor angiogenesis, CAF activity, and tumor
metastasis. (iv) MSC: NR4A1 functions in mediating MSC proliferation and cytokine and growth factor production, leading to cell migration resulting in altered immune
(T regulatory, T cytotoxic, and macrophage) cell function. (v) ECM: cross talk between NR4As and the stroma, including interaction with the ECM, TGFβ/SMAD
signaling, and p53 activity.
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disease progression and tissue response to therapy. Recent
developments discerning NR4A1–NR4A3 receptor function
in cells within the tumor–stromal environment highlight
the distinct functional role(s) that these receptors perform
in modulating pro-inflammatory signaling, proliferation,
hyperplasia, death/survival, migration, angiogenesis, and tumor
immune surveillance. The described NR4A studies uncover the
fundamental molecular mechanisms controlling cell-specific
activity that facilitates tumor–stromal cell communication
within the TME. With the development of mechanism-based
NR4A biologics demonstrating efficacy at transforming
tumor angiogenesis, growth, metastasis, and immune
surveillance, these intracellular receptors may function as
central receptors demonstrating translational capacity in cancer
cell biology.
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